IMMEDIATE-RELEASE NIFEDIPINE LABELING WILL WARN AGAINST OFF-LABEL USES, FDA INDICATES FOLLOWING CALCIUM CHANNEL BLOCKER ADVISORY COMMITTEE REVIEW